select a format

Single User License
USD 2500 INR 161450
Site License
USD 5000 INR 322900
Corporate User License
USD 7500 INR 484350

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Alzheimers Disease-Pipeline Review, H1 2017

Alzheimers Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9058IDB
  • |
  • Pages: 1181
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Alzheimer's Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease-Pipeline Review, H1 2017, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 40, 62, 1, 251, 90 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 109 and 46 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

Introduction 12

Alzheimer's Disease-Overview 13

Alzheimer's Disease-Therapeutics Development 14

Alzheimer's Disease-Therapeutics Assessment 78

Alzheimer's Disease-Companies Involved in Therapeutics Development 102

Alzheimer's Disease-Drug Profiles 218

Alzheimer's Disease-Dormant Projects 1072

Alzheimer's Disease-Discontinued Products 1102

Alzheimer's Disease-Product Development Milestones 1108

Appendix 1118

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Alzheimer's Disease-Pipeline by AB Science SA, H1 2017

Alzheimer's Disease-Pipeline by AbbVie Inc, H1 2017

Alzheimer's Disease-Pipeline by AC Immune SA, H1 2017

Alzheimer's Disease-Pipeline by Acadia Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Accera Inc, H1 2017

Alzheimer's Disease-Pipeline by Acelot Inc, H1 2017

Alzheimer's Disease-Pipeline by Actinogen Medical Ltd, H1 2017

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, H1 2017

Alzheimer's Disease-Pipeline by Affibody AB, H1 2017

Alzheimer's Disease-Pipeline by AFFiRiS AG, H1 2017

Alzheimer's Disease-Pipeline by Alector LLC, H1 2017

Alzheimer's Disease-Pipeline by Allergan Plc, H1 2017

Alzheimer's Disease-Pipeline by Allinky Biopharma, H1 2017

Alzheimer's Disease-Pipeline by ALSP Inc, H1 2017

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, H1 2017

Alzheimer's Disease-Pipeline by Alzinova AB, H1 2017

Alzheimer's Disease-Pipeline by AlzProtect SAS, H1 2017

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Alzheimer's Disease-Pipeline by Amgen Inc, H1 2017

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp, H1 2017

Alzheimer's Disease-Pipeline by Annexon Inc, H1 2017

Alzheimer's Disease-Pipeline by Aphios Corp, H1 2017

Alzheimer's Disease-Pipeline by Apodemus AB, H1 2017

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences SL, H1 2017

Alzheimer's Disease-Pipeline by Aptevo Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Araclon Biotech SL, H1 2017

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by ArmaGen Inc, H1 2017

Alzheimer's Disease-Pipeline by Artery Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Asceneuron SA, H1 2017

Alzheimer's Disease-Pipeline by AskAt Inc, H1 2017

Alzheimer's Disease-Pipeline by Astellas Pharma Inc, H1 2017

Alzheimer's Disease-Pipeline by AstraZeneca Plc, H1 2017

Alzheimer's Disease-Pipeline by Asubio Pharma Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, H1 2017

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd., H1 2017

Alzheimer's Disease-Pipeline by Axxam SpA, H1 2017

Alzheimer's Disease-Pipeline by Beactica AB, H1 2017

Alzheimer's Disease-Pipeline by Berg LLC, H1 2017

Alzheimer's Disease-Pipeline by BioArtic AB, H1 2017

Alzheimer's Disease-Pipeline by Bioasis Technologies Inc, H1 2017

Alzheimer's Disease-Pipeline by Biogen Inc, H1 2017

Alzheimer's Disease-Pipeline by BioHealthonomics Inc, H1 2017

Alzheimer's Disease-Pipeline by Biomar Microbial Technologies, H1 2017

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Alzheimer's Disease-Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Company, H1 2017

Alzheimer's Disease-Pipeline by Bsim2, H1 2017

Alzheimer's Disease-Pipeline by Cantabio Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Cardax Inc, H1 2017

Alzheimer's Disease-Pipeline by Carna Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Celon Pharma SA, H1 2017

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Clera Inc, H1 2017

Alzheimer's Disease-Pipeline by Cognition Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Cognosci Inc, H1 2017

Alzheimer's Disease-Pipeline by CohBar Inc, H1 2017

Alzheimer's Disease-Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Alzheimer's Disease-Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Corium International Inc, H1 2017

Alzheimer's Disease-Pipeline by Coronis NeuroSciences Ltd, H1 2017

Alzheimer's Disease-Pipeline by Cortice Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Critical Outcome Technologies Inc, H1 2017

Alzheimer's Disease-Pipeline by Crossbeta Biosciences BV, H1 2017

Alzheimer's Disease-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Alzheimer's Disease-Pipeline by Daval International Ltd, H1 2017

Alzheimer's Disease-Pipeline by Denali Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by DermaXon LLC, H1 2017

Alzheimer's Disease-Pipeline by Domain Therapeutics SA, H1 2017

Alzheimer's Disease-Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Eisai Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Eli Lilly and Company, H1 2017

Alzheimer's Disease-Pipeline by EncephRx Inc, H1 2017

Alzheimer's Disease-Pipeline by Endece LLC, H1 2017

Alzheimer's Disease-Pipeline by ENKAM Pharmaceuticals A/S, H1 2017

Alzheimer's Disease-Pipeline by Ensemble Therapeutics Corp, H1 2017

Alzheimer's Disease-Pipeline by Ensol Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Epigen Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Evotec AG, H1 2017

Alzheimer's Disease-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Alzheimer's Disease-Pipeline by Genentech Inc, H1 2017

Alzheimer's Disease-Pipeline by Genervon Biopharmaceuticals LLC, H1 2017

Alzheimer's Disease-Pipeline by Genzyme Corp, H1 2017

Alzheimer's Disease-Pipeline by GlaxoSmithKline Plc, H1 2017

Alzheimer's Disease-Pipeline by GliaCure Inc, H1 2017

Alzheimer's Disease-Pipeline by Glialogix Inc, H1 2017

Alzheimer's Disease-Pipeline by Golden Biotechnology Corp, H1 2017

Alzheimer's Disease-Pipeline by Grifols SA, H1 2017

Alzheimer's Disease-Pipeline by H. Lundbeck A/S, H1 2017

Alzheimer's Disease-Pipeline by Heptares Therapeutics Ltd, H1 2017

Alzheimer's Disease-Pipeline by HitGen LTD, H1 2017

Alzheimer's Disease-Pipeline by HSRx Group, H1 2017

Alzheimer's Disease-Pipeline by ICB International Inc, H1 2017

Alzheimer's Disease-Pipeline by Ichor Medical Systems Inc, H1 2017

Alzheimer's Disease-Pipeline by Icure Pharmaceutical Inc, H1 2017

Alzheimer's Disease-Pipeline by Immungenetics AG, H1 2017

Alzheimer's Disease-Pipeline by Impel NeuroPharma Inc, H1 2017

Alzheimer's Disease-Pipeline by ImStar Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by IntelGenx Corp, H1 2017

Alzheimer's Disease-Pipeline by Intellect Neurosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Intra-Cellular Therapies Inc, H1 2017

Alzheimer's Disease-Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Io Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Johnson & Johnson, H1 2017

Alzheimer's Disease-Pipeline by K-Stemcell Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Kadmon Corp LLC, H1 2017

Alzheimer's Disease-Pipeline by Kalgene Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Kareus Therapeutics SA, H1 2017

Alzheimer's Disease-Pipeline by Karuna Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by KineMed Inc, H1 2017

Alzheimer's Disease-Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Lead Discovery Center GmbH, H1 2017

Alzheimer's Disease-Pipeline by Les Laboratoires ServierSAS, H1 2017

Alzheimer's Disease-Pipeline by Lipopharma Therapeutics SL, H1 2017

Alzheimer's Disease-Pipeline by Living Cell Technologies Ltd, H1 2017

Alzheimer's Disease-Pipeline by Lupin Ltd, H1 2017

Alzheimer's Disease-Pipeline by M3 Biotechnology Inc, H1 2017

Alzheimer's Disease-Pipeline by ManRos Therapeutics, H1 2017

Alzheimer's Disease-Pipeline by MedDay SA, H1 2017

Alzheimer's Disease-Pipeline by Medestea Research & Production SpA, H1 2017

Alzheimer's Disease-Pipeline by MedImmune LLC, H1 2017

Alzheimer's Disease-Pipeline by Medisyn Technologies Inc, H1 2017

Alzheimer's Disease-Pipeline by MEDRx Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by MEI Pharma Inc, H1 2017

Alzheimer's Disease-Pipeline by MeiraGTx Ltd, H1 2017

Alzheimer's Disease-Pipeline by Merck & Co Inc, H1 2017

Alzheimer's Disease-Pipeline by Metabolic Solutions Development Company LLC, H1 2017

Alzheimer's Disease-Pipeline by Microlin Bio Inc, H1 2017

Alzheimer's Disease-Pipeline by Mithridion Inc, H1 2017

Alzheimer's Disease-Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Alzheimer's Disease-Pipeline by ModGene Pharma LLC, H1 2017

Alzheimer's Disease-Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Alzheimer's Disease-Pipeline by Nanomerics Ltd, H1 2017

Alzheimer's Disease-Pipeline by Nanotherapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Neuralstem Inc, H1 2017

Alzheimer's Disease-Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Alzheimer's Disease-Pipeline by Neuro-Sys SAS, H1 2017

Alzheimer's Disease-Pipeline by NeuroGenetic Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by NeuroNascent Inc, H1 2017

Alzheimer's Disease-Pipeline by NeurOp Inc, H1 2017

Alzheimer's Disease-Pipeline by Neuropore Therapies Inc, H1 2017

Alzheimer's Disease-Pipeline by Neurotez Inc, H1 2017

Alzheimer's Disease-Pipeline by New World Laboratories Inc, H1 2017

Alzheimer's Disease-Pipeline by nLife Therapeutics SL, H1 2017

Alzheimer's Disease-Pipeline by NLS Pharma Group, H1 2017

Alzheimer's Disease-Pipeline by Novartis AG, H1 2017

Alzheimer's Disease-Pipeline by NsGene A/S, H1 2017

Alzheimer's Disease-Pipeline by Oligomerix inc, H1 2017

Alzheimer's Disease-Pipeline by Orphit SAS, H1 2017

Alzheimer's Disease-Pipeline by Oryzon Genomics SA, H1 2017

Alzheimer's Disease-Pipeline by P2D Bioscience, H1 2017

Alzheimer's Disease-Pipeline by Pain Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Palumed SA, H1 2017

Alzheimer's Disease-Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Peptron Inc, H1 2017

Alzheimer's Disease-Pipeline by Pfizer Inc, H1 2017

Alzheimer's Disease-Pipeline by PharmaKure Ltd, H1 2017

Alzheimer's Disease-Pipeline by PharmatrophiX Inc, H1 2017

Alzheimer's Disease-Pipeline by Pharmaxis Ltd, H1 2017

Alzheimer's Disease-Pipeline by Pharnext SA, H1 2017

Alzheimer's Disease-Pipeline by Prevacus Inc, H1 2017

Alzheimer's Disease-Pipeline by Probiodrug AG, H1 2017

Alzheimer's Disease-Pipeline by Proclara Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Progenra Inc, H1 2017

Alzheimer's Disease-Pipeline by ProMIS Neurosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by ProQR Therapeutics NV, H1 2017

Alzheimer's Disease-Pipeline by Proteome Sciences Plc, H1 2017

Alzheimer's Disease-Pipeline by Proteostasis Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by QR Pharma Inc, H1 2017

Alzheimer's Disease-Pipeline by Quimatryx SL, H1 2017

Alzheimer's Disease-Pipeline by Radius Health Inc, H1 2017

Alzheimer's Disease-Pipeline by Regenera Pharma Ltd, H1 2017

Alzheimer's Disease-Pipeline by reMYND NV, H1 2017

Alzheimer's Disease-Pipeline by Resverlogix Corp, H1 2017

Alzheimer's Disease-Pipeline by Retrotope Inc, H1 2017

Alzheimer's Disease-Pipeline by ReXceptor Inc, H1 2017

Alzheimer's Disease-Pipeline by Rodos BioTarget GmbH, H1 2017

Alzheimer's Disease-Pipeline by Sage Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Samumed LLC, H1 2017

Alzheimer's Disease-Pipeline by SanBio Inc, H1 2017

Alzheimer's Disease-Pipeline by Saneron CCEL Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Sanofi, H1 2017

Alzheimer's Disease-Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Selvita SA, H1 2017

Alzheimer's Disease-Pipeline by SeneXta Therapeutics SA, H1 2017

Alzheimer's Disease-Pipeline by Serometrix LLC, H1 2017

Alzheimer's Disease-Pipeline by Signum Biosciences Inc, H1 2017

Alzheimer's Disease-Pipeline by Simcere Pharmaceutical Group, H1 2017

Alzheimer's Disease-Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by SOM Biotech SL, H1 2017

Alzheimer's Disease-Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by Spherium Biomed SL, H1 2017

Alzheimer's Disease-Pipeline by Stemedica Cell Technologies Inc, H1 2017

Alzheimer's Disease-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Summit Therapeutics Plc, H1 2017

Alzheimer's Disease-Pipeline by Suven Life Sciences Ltd, H1 2017

Alzheimer's Disease-Pipeline by T3D Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Alzheimer's Disease-Pipeline by TauRx Therapeutics Ltd, H1 2017

Alzheimer's Disease-Pipeline by TechnoPhage SA, H1 2017

Alzheimer's Disease-Pipeline by Teijin Pharma Ltd, H1 2017

Alzheimer's Disease-Pipeline by Teikoku Pharma USA Inc, H1 2017

Alzheimer's Disease-Pipeline by Telocyte LLC, H1 2017

Alzheimer's Disease-Pipeline by Tetra Discovery Partners LLC, H1 2017

Alzheimer's Disease-Pipeline by Thera Neuropharma Inc, H1 2017

Alzheimer's Disease-Pipeline by Theranexus SAS, H1 2017

Alzheimer's Disease-Pipeline by Therapix Biosciences Ltd, H1 2017

Alzheimer's Disease-Pipeline by Toyama Chemical Co Ltd, H1 2017

Alzheimer's Disease-Pipeline by Treventis Corp, H1 2017

Alzheimer's Disease-Pipeline by UCB SA, H1 2017

Alzheimer's Disease-Pipeline by Varinel Inc, H1 2017

Alzheimer's Disease-Pipeline by Virobay Inc, H1 2017

Alzheimer's Disease-Pipeline by Vitae Pharmaceuticals Inc, H1 2017

Alzheimer's Disease-Pipeline by VLP Therapeutics LLC, H1 2017

Alzheimer's Disease-Pipeline by Voyager Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by vTv Therapeutics Inc, H1 2017

Alzheimer's Disease-Pipeline by Vybion Inc, H1 2017

Alzheimer's Disease-Pipeline by Wellstat Therapeutics Corp, H1 2017

Alzheimer's Disease-Pipeline by Xigen SA, H1 2017

Alzheimer's Disease-Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..1), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..2), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..3), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..4), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..5), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..6), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..7), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..8), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..9), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..10), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..11), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..12), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..13), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..14), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..15), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..16), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..17), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..18), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..19), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..20), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..21), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..22), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..23), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..24), H1 2017

Alzheimer's Disease-Dormant Projects, H1 2017 (Contd..25), H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017 (Contd..1), H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017 (Contd..2), H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017 (Contd..3), H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017 (Contd..4), H1 2017

Alzheimer's Disease-Discontinued Products, H1 2017 (Contd..5), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA, AbbVie Inc, AC Immune SA, Acadia Pharmaceuticals Inc, Accera Inc, Acelot Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Affibody AB, AFFiRiS AG, Alector LLC, Allergan Plc, Allinky Biopharma, ALSP Inc, Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings Inc, Amgen Inc, Anavex Life Sciences Corp, Annexon Inc, Aphios Corp, Apodemus AB, Applied Research using OMIC Sciences SL, Aptevo Therapeutics Inc, Araclon Biotech SL, Archer Pharmaceuticals Inc, ArmaGen Inc, Artery Therapeutics Inc, Asceneuron SA, AskAt Inc, Astellas Pharma Inc, AstraZeneca Plc, Asubio Pharma Co Ltd, Avineuro Pharmaceuticals Inc, Axon Neuroscience SE, Axovant Sciences Ltd., Axxam SpA, Beactica AB, Berg LLC, BioArtic AB, Bioasis Technologies Inc, Biogen Inc, BioHealthonomics Inc, Biomar Microbial Technologies, Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, Bsim2, Cantabio Pharmaceuticals Inc, Cardax Inc, Carna Biosciences Inc, Celon Pharma SA, CHA Bio & Diostech Co Ltd, Clera Inc, Cognition Therapeutics Inc, Cognosci Inc, CohBar Inc, Connexios Life Sciences Pvt Ltd, ContraVir Pharmaceuticals Inc, Corium International Inc, Coronis NeuroSciences Ltd, Cortice Biosciences Inc, Critical Outcome Technologies Inc, Crossbeta Biosciences BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, Daval International Ltd, Denali Therapeutics Inc, DermaXon LLC, Domain Therapeutics SA, Dongkook Pharmaceutical Co Ltd, Eisai Co Ltd, Eli Lilly and Company, EncephRx Inc, Endece LLC, ENKAM Pharmaceuticals A/S, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Epigen Biosciences Inc, Evotec AG, F. Hoffmann-La Roche Ltd, Genentech Inc, Genervon Biopharmaceuticals LLC, Genzyme Corp, GlaxoSmithKline Plc, GliaCure Inc, Glialogix Inc, Golden Biotechnology Corp, Grifols SA, H. Lundbeck A/S, Heptares Therapeutics Ltd, HitGen LTD, HSRx Group, ICB International Inc, Ichor Medical Systems Inc, Icure Pharmaceutical Inc, Immungenetics AG, Impel NeuroPharma Inc, ImStar Therapeutics Inc, Inovio Pharmaceuticals Inc, IntelGenx Corp, Intellect Neurosciences Inc, Intra-Cellular Therapies Inc, INVENT Pharmaceuticals Inc, Io Therapeutics Inc, Ironwood Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, K-Stemcell Co Ltd, Kadmon Corp LLC, Kalgene Pharmaceuticals Inc, Kareus Therapeutics SA, Karuna Pharmaceuticals Inc, KineMed Inc, Krenitsky Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Les Laboratoires ServierSAS, Lipopharma Therapeutics SL, Living Cell Technologies Ltd, Lupin Ltd, M3 Biotechnology Inc, ManRos Therapeutics, MedDay SA, Medestea Research & Production SpA, MedImmune LLC, Medisyn Technologies Inc, MEDRx Co Ltd, MEI Pharma Inc, MeiraGTx Ltd, Merck & Co Inc, Metabolic Solutions Development Company LLC, Microlin Bio Inc, Mithridion Inc, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, ModGene Pharma LLC, NAL Pharmaceuticals Ltd, Nanomerics Ltd, Nanotherapeutics Inc, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neurim Pharmaceuticals Ltd, Neuro-Sys SAS, NeuroGenetic Pharmaceuticals Inc, NeuroNascent Inc, NeurOp Inc, Neuropore Therapies Inc, Neurotez Inc, New World Laboratories Inc, nLife Therapeutics SL, NLS Pharma Group, Novartis AG, NsGene A/S, Oligomerix inc, Orphit SAS, Oryzon Genomics SA, P2D Bioscience, Pain Therapeutics Inc, Palumed SA, Panacea Pharmaceuticals Inc, Peptron Inc, Pfizer Inc, PharmaKure Ltd, PharmatrophiX Inc, Pharmaxis Ltd, Pharnext SA, Prevacus Inc, Probiodrug AG, Proclara Biosciences Inc, Progenra Inc, ProMIS Neurosciences Inc, ProQR Therapeutics NV, Proteome Sciences Plc, Proteostasis Therapeutics Inc, QR Pharma Inc, Quimatryx SL, Radius Health Inc, Regenera Pharma Ltd, reMYND NV, Resverlogix Corp, Retrotope Inc, ReXceptor Inc, Rodos BioTarget GmbH, Sage Therapeutics Inc, Samjin Pharmaceutical Co Ltd, Samumed LLC, SanBio Inc, Saneron CCEL Therapeutics Inc, Sanofi, SBI Pharmaceuticals Co Ltd, Selvita SA, SeneXta Therapeutics SA, Serometrix LLC, Signum Biosciences Inc, Simcere Pharmaceutical Group, SK Biopharmaceuticals Co Ltd, SOM Biotech SL, Spectrum Pharmaceuticals Inc, Spherium Biomed SL, Stemedica Cell Technologies Inc, Sumitomo Dainippon Pharma Co Ltd, Summit Therapeutics Plc, Suven Life Sciences Ltd, T3D Therapeutics Inc, Takeda Pharmaceutical Company Ltd, TauRx Therapeutics Ltd, TechnoPhage SA, Teijin Pharma Ltd, Teikoku Pharma USA Inc, Telocyte LLC, Tetra Discovery Partners LLC, Thera Neuropharma Inc, Theranexus SAS, Therapix Biosciences Ltd, Toyama Chemical Co Ltd, Treventis Corp, UCB SA, Varinel Inc, Virobay Inc, Vitae Pharmaceuticals Inc, VLP Therapeutics LLC, Voyager Therapeutics Inc, vTv Therapeutics Inc, Vybion Inc, Wellstat Therapeutics Corp, Xigen SA, Zhejiang Hisun Pharmaceutical Co Ltd

Alzheimer's Disease Therapeutic Products under Development, Key Players in Alzheimer's Disease Therapeutics, Alzheimer's Disease Pipeline Overview, Alzheimer's Disease Pipeline, Alzheimer's Disease Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com